(MEMPHIS, Tenn. – June 17, 2025) Single-cell RNA sequencing provides scientists with important information about gene expression in health and disease. However, the technique is expensive and often prohibits analysis of large numbers of cells. Scientists from St. Jude Children’s Research Hospital, the National Center for Genomic Analysis and the University of Adelaide created a method that combines microscopy with single-cell RNA analysis to overcome these limitations. The technique called Single-Cell Transcriptomics Analysis and Multimodal Profiling through Imaging (STAMP) can look at millions of single cells for a fraction of the cost of existing approaches. The work was published today in Cell.
“We’ve created a technique that gives us an advantage in the numbers game of single-cell analysis,” said co-corresponding author Jasmine Plummer, PhD, St. Jude Center for Spatial Omics director and Department of Developmental Neurobiology member. “It’s an order of magnitude more cost-effective and allows us to profile a million cells simultaneously, compared to tens of thousands typical of current methods, making it far more scalable.”
The researchers separated cells from tissues until they were individual, unconnected cells. They then fixed or “stamped” those cells onto microscopy slides, which kills the cells but “locks” them in time, including their shapes and expressed genes. The scientists then added molecules that light up under a microscope when bonded to specific RNA sequences. The researchers compared their results to published atlases of gene expression data, finding they could characterize many immune cells simultaneously and discriminate between the developmental stages of induced pluripotent stem cells. They calculated that analyzing the immune cells from 1,000 individuals would normally cost $3.56 million while scaling STAMP to do the same analysis would cost $75,000, a 47-fold reduction.
STAMPing out bias in single-cell analysis while maintaining sensitivity
“Current techniques for single-cell RNA sequencing require inference to determine things such as cell type, but STAMP allows us to directly examine the cells,” Plummer said. “Many current single-cell approaches also bias results based on cell shape, often missing irregularly shaped cells including neurons.”
Conventional RNA-sequencing techniques require cells to move through a tube before being analyzed. The more spherical and simpler the shape, the better the cell moves through these machines, causing some bias in results. The STAMP technique is performed on a microscope slide, avoiding this issue and allowing more diverse cell types to be represented.
To ensure sensitivity is also maintained, the researchers diluted cancer cells into a suspension of many other cells. STAMP detected two cancer cells within approximately 850,000 total cells on a single slide.
“Being able to profile a million cells is crucial because it only takes one cell to escape cancer treatment,” Plummer said. “We’ve shown STAMP allows us to visualize and detect these cells in a numerically advantageous and accessible way, an important feature for potential future development into clinical applications.”
Single-cell RNA sequencing remains prohibitively expensive, especially for those without access to the funding, specialized equipment or computational infrastructure it typically requires. However, almost all research institutions have easy access to microscopes.
“We as scientists believe what we can see,” Plummer said. “STAMP gives us the best of both worlds in single-cell analysis: quantitative gene expression data and the ability to visually examine the cells under a microscope. We hope that these features, combined with its accessibility and cost-effectiveness, enable others to discover new biology and clinical uses in the future.”
Authors and funding
The study’s co-first authors are Emanuele Pitino and Anna Pascual-Reguant, Centro Nacional de Análisis Genómico and Felipe Segato Dezem, St. Jude. The study’s other co-corresponding authors are Holger
Heyn, Centro Nacional de Análisis Genómico and Luciano Martelotto, The University of Adelaide. The study’s other authors are Irepan Salvador-Martinez, Helena Lucia Crowell, Sara Ruiz, Ginevra Caratù and Juan Nieto, Centro Nacional de Análisis Genómico and Universitat de Barcelona; Maycon Marção, Yutian Liu and Hannah Chasteen, St. Jude, Kellie Wise, German Mora Roldan, Kate Dredge, Monika Mohenska, José Polo and Adrienne Sullivan, University of Adelaide; Elise Courtois, William Flynn and Santhosh Sivajothi, The Jackson Laboratory for Genomic Medicine; Emily Soja, Monash University; Raymond Yip and Ruvimbo Mishi, Walter and Eliza Hall Institute of Medical Research and Mohmed Abdalfttah, Spanish National Cancer Research Centre.
The study was supported by grants from the Commonwealth Standard Grant Agreement (4-F26M8TZ), the Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, FSE+ (RYC2022-035848-I), MICIU/AEI/10.13039/501100011033/FEDER/UE (PID2023-148687OBI00), (PID2020-115439GB-I00)), the European Union’s Horizon 2020 research and innovation programme (848028 and 810287), the European Union’s Horizon Europe research and innovation programme (101072891), the Australian Government through the South Australian immunoGENomics Cancer Institute (SAiGENCI), the Swiss National Science Foundation (222136), the Ovarian Cancer Research Alliance (ECIG-2022-3-1143), the Chan Zuckerberg Foundation (OS00001235 and 2024-345901) and the JAX Cancer Center (P30CA034196).
If you are interested in licensing STAMP (Single-Cell Transcriptomics Analysis and Multimodal Profiling) (SJ-25-0018) for further development and/or commercial use, find out more about licensing.
St. Jude Media Relations contacts
Chelsea Bryant
Desk: (901) 595-0564
chelsea.bryant@stjude.org
media@stjude.org
Rae Lyn Hartley
Cell: (901) 686-2597
raelyn.hartley@stjude.org
media@stjude.org
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media at @stjuderesearch.
END